Next Generation Bio-Innovation: Delivering Commercial Value

Report an error

Summary

AI-generated

This summary is written by a language model reading the source document. It is not the publisher's words and is not a substitute for the original.

Learn more about AI enrichment

The briefing paper contends that the bioeconomy has failed to drive meaningful transformation because it lacks a compelling articulation of commercial value. It proposes a framework for value creation based on two lenses: product properties (categorized as bio-derived, bio-improved, bio-superior, and bio-disruptive) and production systems (focusing on resilience, cost, and efficiency). The authors argue that for bio-innovation to move beyond the 'valley of death,' it must integrate these value drivers early in the design process rather than relying on 'green premiums' or technical feasibility alone.

Key insights

AI-generated

These insights are written by a language model reading the source document. They are not the publisher's words and are not a substitute for the original.

Learn more about AI enrichment
  • Bio-innovation currently suffers from a 'technology-push' environment where developments are often misaligned with existing demand or fail to create new demand, hindering its ability to break through industries.
  • The document identifies a significant funding gap and scaling challenge known as the 'valley of death,' which bio-innovation must overcome by refocusing on unique value creation to achieve profitable growth.
  • Commercial value in biology is categorized into two synergistic lenses: product properties, which create superior or novel items for customers, and production systems, which enhance operational resilience and reduce costs for businesses.
  • The paper proposes a four-tier framework for customer value: bio-derived (drop-in replacements), bio-improved (enhanced perceived value like ethical or cleaner production), bio-superior (improved functional performance), and bio-disruptive (entirely new use cases).
  • Production system value is critical for commercial viability, especially for high-cost innovations, as 'green premiums' are insufficient to drive meaningful market transformation.
  • The integration of biology with convergent technologies—including AI, synthetic biology, robotics, and additive manufacturing—is essential for transforming production systems and meeting unmet needs.

Cite the original document

APA
World Economic Forum (2025). Next Generation Bio-Innovation: Delivering Commercial Value. https://reports.weforum.org/docs/WEF_Next_Generation_Bio_Innovation_2025.pdf
Chicago
World Economic Forum. Next Generation Bio-Innovation: Delivering Commercial Value. 2025. https://reports.weforum.org/docs/WEF_Next_Generation_Bio_Innovation_2025.pdf.
Wikipedia
{{cite report |author=World Economic Forum |title=Next Generation Bio-Innovation: Delivering Commercial Value |date=June 2025 |url=https://reports.weforum.org/docs/WEF_Next_Generation_Bio_Innovation_2025.pdf |access-date=23 October 2026 |via=Climate Insights Directory}}
BibTeX
@techreport{worldeconomicforum2025next, author = {{World Economic Forum}}, title = {{Next Generation Bio-Innovation: Delivering Commercial Value}}, institution = {World Economic Forum}, year = {2025}, month = jun, url = {https://reports.weforum.org/docs/WEF_Next_Generation_Bio_Innovation_2025.pdf}, urldate = {2026-10-23}, note = {Indexed by Climate Insights Directory} }

Full text

Collected · Record updated